Since joining Kirkland, Merric has been involved in the following matters:
- Sage Therapeutics (Nasdaq: SAGE), a biopharmaceutical company, in its pending $795 million sale to Supernus Pharmaceuticals (Nasdaq: SUPN)
- Anne Wojcicki's not-for-profit TTAM Research Institute in its pending acquisition of 23andMe, a human genetics and biotechnology company
Prior to joining Kirkland, Merric was involved in the following representations:
- Centerview Partners and Jefferies as financial advisors to Intra-Cellular Therapies (Nasdaq: ITCI) in its $14.3 billion acquisition by Johnson & Johnson (NYSE: JNJ)
- Vertex Pharmaceuticals (Nasdaq: VRTX) in its $4.9 billion acquisition of Alpine Immune Sciences (Nasdaq: ALPN)
- MorphoSys (FSE: MOR; Nasdaq: MOR) in its $2.9 billion sale to Novartis (NYSE: NVS) and simultaneous disposition of Monjuvi to Incyte (Nasdaq: INCY)
- POINT Biopharma (Nasdaq: PNT) in its sale to Eli Lilly (NYSE: LLY) for approximately $1.4 billion
- Iveric Bio (Nasdaq: ISEE) in its $5.9 billion sale to Astellas (TSE: 4503)
- Centerview Partners as financial advisor to Seagen (Nasdaq: SGEN) in its $43 billion acquisition by Pfizer (NYSE: PFE)
- Vertex Pharmaceuticals (Nasdaq: VRTX) in its $320 million acquisition of ViaCyte
- Bottomline Technologies (Nasdaq: EPAY) in its acquisition by Thoma Bravo for $2.6 billion
- AspenTech (Nasdaq: AZPN) in its $11 billion combination with Emerson Electric's (NYSE: EMR) industrial software business
- MorphoSys (FSE: MOR; Nasdaq: MOR) in its $1.7 billion acquisition of Constellation Pharmaceuticals (Nasdaq: CNST) and its related financing from Royalty Pharma (Nasdaq: RPRX) totaling over $2 billion
- WeWork (NYSE: WE) in various transactions including its merger with BowX Acquisition Corp., a special purpose acquisition company, as a result of which WeWork became a public company with an implied initial enterprise value of $9 billion
- The special committee of the board of directors of National Holdings Corporation (Nasdaq: NHLD) in connection with the acquisition by B. Riley Financial (Nasdaq: RILY) of the remaining stock of National Holdings
- JLL Partners in its acquisition of Jonathan Engineered Solutions, a designer and manufacturer of enclosures for defense, commercial aerospace and specialty industrial end markets; and two add-on transactions for Secretariat Advisors, a specialty consulting firm
- Ionis Pharmaceuticals (Nasdaq: IONS) in its acquisition of the remaining outstanding stake of Akcea Therapeutics (Nasdaq: AKCA) for $500 million
- CerSci Therapeutics in its sale to Acadia Pharmaceuticals (Nasdaq: ACAD) for up to $939.5 million
- Gilead Sciences (Nasdaq: GILD) in its $4.9 billion acquisition of Forty Seven (Nasdaq: FTSV)
- ArQule (Nasdaq: ARQL) in its sale to Merck (NYSE: MRK) for $2.7 billion
- Alder BioPharmaceuticals (Nasdaq: ALDR) in its sale to Lundbeck for up to $1.95 billion
- Nightstar Therapeutics (NST: NITE; Nasdaq: NITE) in its $800 million sale to Biogen (Nasdaq: BIIB)
- Carbonite (Nasdaq: CARB) in its $618.5 million acquisition of Webroot
